Salute e Benessere

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – July 22, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 18, 2025, from Atlas Special…
Actusnews Wire
22/07/2025

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNTAND NEW NUMBER OF SHARES Ghent, Belgium, 22 July 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that in the context of contributions in kind of certain receivables (for an aggregate amount of EUR 963,000.00) due under the convertible loan agreement entered into on…
Nasdaq GlobeNewswire
22/07/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from July 14th to July 18th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 240 105,775...
Nasdaq GlobeNewswire
22/07/2025

Virtual TRY-ON Technology Market Size to Grow USD 27710 Million by 2031 at a…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-25X13456/Global_Virtual_TRY_ON_technology_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-25X13456/Global_Virtual_TRY_ON_technology_Market Major Factors Driving the Growth of Virtual TRY-ON Technology Market: The virtual try-on technology market is evolving into a critical component of the global retail ecosystem. As consumers demand immersive, accurate, and...
PR Newswire
22/07/2025

Pharmaceutical Excipients Market worth $14.9 billion by 2030 with 6.1% CAGR |…

Browse in-depth TOC on "Pharmaceutical Excipients Market" Browse in-depth TOC on "Pharmaceutical Excipients Market" 550 - Tables60 - Figures 515 - Pages By product,the global pharmaceutical excipients market is segmented by product type into three main categories: organic chemicals, inorganic chemicals, and other chemicals. Among these, organic chemicals comprise compounds primarily made up of carbon atoms bonded with other elements through covalent bonds. These...
PR Newswire
22/07/2025

BostonGene Receives Frost & Sullivan's 2025 North American Enabling Technology…

BostonGene combines data from genes, RNA, proteins, the immune system and the tumor environment to help pharma and biotech develop targeted therapies, design efficient trials, and improve outcomes. Its "Comprehensive Digital Patient" model enables precise drug targeting, biomarker validation and patient stratification. With high test success and fast turnaround, BostonGene accelerates data-driven clinical decisions. BostonGene combines data from genes, RNA, proteins, the immune system…
PR Newswire
22/07/2025

From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits

Currently, the AI in healthcare sector projected to surpass $110 billion by 2030. However, according to Accenture, artificial intelligence could unlock an additional $461 billion in value across healthcare by 2035—on top of a sector already projected to surpass $2.26 trillion. Currently, the AI in healthcare sector projected to surpass $110 billionby 2030. However, according toAccenture, artificial intelligence could unlock anadditional$461 billion in value across healthcare by...
PR Newswire
22/07/2025

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create…

Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech…
PR Newswire
22/07/2025

Kolmar Korea Launches Full Operation of 2nd US Factory, Establishing K-Beauty's…

The ceremony was attended by Vice Chairman Yoon, Pennsylvania State Representative Bridget Kosierowski, state government officials, and affiliated organizations — with around 100 participants present. The ceremony was attended by Vice Chairman Yoon, Pennsylvania State RepresentativeBridget Kosierowski, state government officials, and affiliated organizations — with around 100 participants present. The newly completed facility spans 17,805㎡ (191,651 square feet) with an annual production...
PR Newswire
22/07/2025

Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

"Over the past few years Abzena has made incredible progress driving operational execution and strengthening our unique scientific capabilities, the combination of which has resulted in delighting many of our customers," said Mr. Glass. "Those efforts have also led to significant growth. I have had the privilege of working alongside this team as Chairman, and I am honored to join as CEO to help continue our momentum. I look forward to working even more closely with our talented…
PR Newswire
22/07/2025

Unchained Labs drops Stunner AF and new Sunshine flavors to crush therapeutic…

When it comes to making the perfect therapeutic nanoparticle, Sunshine's got a researcher's back. Whether they're testing out their payload, dialing in flow rates, switching up mixing methods, starting to scale up or nailing the sweet spot for dilution, there's a Sunshine that will help them find their recipe fast. There's Sunshine Single for quick, one-off automated runs, Sunshine Lite for automated runs of multiple experiments, all the way to the full-on Sunshine that adds on continuous flow…
PR Newswire
22/07/2025

uniQure to Announce Second Quarter 2025 Financial Results

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET.The event will be webcast under the Events & Presentations section of uniQure’s website at...
Nasdaq GlobeNewswire
22/07/2025

Medical Coating Market worth $15,813.6 million by 2030 - Exclusive Report by…

Browse in-depth TOC on "Medical Coating Market" Browse in-depth TOC on "Medical Coating Market" 300 - Tables50 - Figures179 - Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76047356 Metals will account for the second-largest share in the medical coating market by material during the forecast period, in terms of value. Metals are expected to hold the second-largest share of the medical coating market, by material, during the...
PR Newswire
22/07/2025

WuXi Biologics Secures FDA PLI Approval for Five Facilities, First for…

As of late 2024, WuXi Biologics has successfully passed 42 regulatory inspections, including 22 by the EU EMA and the FDA. Additionally, the company has received 97 license approvals from regulatory agencies around the world. As of late 2024, WuXi Biologics has successfully passed 42 regulatory inspections, including 22 by the EU EMA and the FDA. Additionally, the company has received 97 license approvals from regulatory agencies around the world. Dr.Chris Chen, CEO of WuXi Biologics,...
PR Newswire
22/07/2025

SkylineDx's Merlin Melanoma Assay shows its ability to reduce SLNB by over 40%…

Key findings of the study include: Key findings of the study include: " The Merlin test is a promising and well-validated non-invasive tool for refining SLNB selection, with consistent findings across several independent cohorts," said First Author Dr. Marie B.-M. Weitemeyer fromCopenhagen UniversityHospital-Herlev and Gentofte. "In our Danish cohort, Merlin demonstrated the potential to reduce unnecessary SLNB procedures by more than 40%." "Merlin performance is…
PR Newswire
22/07/2025

Oxurion overweegt een strategie voor diversificatie van zijn kasmiddelen in…

Deze stap kadert in een langetermijnstrategie voor financiële consolidatie en groeiondersteuning. Oxurion start onderhandelingen met Atlas Special Opportunities voor een nieuw converteerbaar obligatieprogramma van in totaal €10 miljoen, in schijven van €1 miljoen, converteerbaar met een premie van 10% ten opzichte van het volumegewogen gemiddelde…
Actusnews Wire
22/07/2025

Oxurion plans to launch a treasury diversification strategy into digital assets…

This initiative is part of a long-term strategy for financial consolidation and growth support. Oxurion enters negotiations with Atlas Special Opportunities for a new €10 million convertible bond program, in €1 million tranches, convertible with a 10% premium over the 15-day volume-weighted average price (VWAP) The proceeds from the issuance are…
Actusnews Wire
22/07/2025

Lecanemab four-year efficacy and safety data to be presented at AAIC 2025

Key Lecanemab Poster Presentation at AAIC Key Lecanemab Poster Presentation at AAIC Eisai serves as the lead of Leqembi development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. The information was...
PR Newswire
22/07/2025

Bavarian Nordic Receives Acceptance from Health Canada for Review of the New…

COPENHAGEN, Denmark, July 22, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) chikungunya vaccine candidate, CHIKV VLP, for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older. The application screening acceptance by the Directorate confirms that the New Drug Submission is complete and begins a...
Nasdaq GlobeNewswire
22/07/2025

Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6…

Vicebio is currently running an exploratory Phase 1 clinical trial with lead asset VXB-241, a bivalent vaccine targeting both RSV and hMPV viruses, pathogens that are a significant burden in the elderly and those with a weakened immune system. Interim analysis of the exploratory Phase 1 study showed a favourable safety and tolerability profile in adults aged 60 and above. Vicebio is currently running an exploratory Phase 1 clinical trial with lead asset VXB-241, a bivalent vaccine targeting...
PR Newswire
22/07/2025

Embla Medical hf: Interim Report Q2 2025

22 July 2025 22 July 2025 COPENHAGEN, Denmark , July 22, 2025 /PRNewswire/ -- Sveinn Sölvason, President and CEO, comments: "Sales in Q2 2025 amounted toUSD 232 million, representing 7% reported growth, of which 5% was organic. Growth was strong in the Prosthetics & Neuro Orthotics segment, primarily driven by continued momentum in EMEA and supported by solid contribution from our recently launched innovation. Growth in Americas and APAC regions was also good, led...
PR Newswire
22/07/2025

Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines…

Sanofi to acquire Vicebio, expanding respiratory vaccines pipelineParis, July 22, 2025.Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with...
Nasdaq GlobeNewswire
22/07/2025

Neuraxpharm continues international expansion with launch of Neuraxpharm…

SYDNEY and DÜSSELDORF, Germany, July 21, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally. SYDNEYand DÜSSELDORF,Germany , July 21, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading...
PR Newswire
22/07/2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the…

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practiceCAMBRIDGE, Mass., July21, 2025(GLOBE NEWSWIRE) --Biogen Inc.(Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association...
Nasdaq GlobeNewswire
22/07/2025
Altri  Comunicati